Core Viewpoint - The Gross Law Firm is notifying shareholders of Aquestive Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's New Drug Application for Anaphylm, which led to a significant drop in stock price [1][3]. Group 1: Allegations and Impact - Shareholders who purchased shares of AQST between June 16, 2025, and January 8, 2026, are encouraged to contact the firm for possible lead plaintiff appointment [1][3]. - The complaint alleges that Aquestive provided positive statements while concealing material adverse facts about the Anaphylm NDA, particularly regarding human factors in its use and deployment [3]. - Following the announcement of deficiencies identified by the FDA on January 9, 2026, the stock price of Aquestive fell from $6.21 to $3.91, a decline of over 37% in one day [3]. Group 2: Next Steps for Shareholders - The deadline for shareholders to register for the class action is May 4, 2026, and there is no cost or obligation to participate [4]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit by a specified deadline [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Aquestive and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until May 4, 2026, to request appointment as Lead Plaintiff if they purchased or acquired Aquestive securities during the Class Period [2]. Group 2: Company Performance and Regulatory Issues - On January 9, 2026, Aquestive received a letter from the U.S. FDA identifying deficiencies that delayed discussions on labeling for Anaphylm (Dibutepinephrine) sublingual film, which had a New Drug Application submitted [4]. - Following the FDA's letter, Aquestive's stock price fell by $2.30 per share, or 37.04%, closing at $3.91 per share on January 9, 2026 [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Aquestive Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's New Drug Application for Anaphylm, which led to a significant drop in stock price [1][3]. Group 1: Allegations and Impact - Shareholders who purchased shares of AQST between June 16, 2025, and January 8, 2026, are encouraged to contact the firm for possible lead plaintiff appointment [1][4]. - The complaint alleges that Aquestive provided positive statements while concealing material adverse facts about the Anaphylm NDA, particularly regarding human factors in its use and deployment [3]. - Following the announcement of deficiencies identified by the FDA on January 9, 2026, the stock price of Aquestive fell from $6.21 to $3.91, a decline of over 37% in one day [3]. Group 2: Next Steps for Shareholders - The deadline for shareholders to register for the class action is May 4, 2026, and they will be enrolled in a portfolio monitoring software for updates [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - A securities class action lawsuit has been filed against Aquestive Therapeutics, Inc. on behalf of investors who purchased or acquired its securities between June 16, 2025, and January 8, 2026, alleging violations of the Securities Exchange Act of 1934 [1][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey, claiming that the company and certain senior officers made misrepresentations regarding the New Drug Application for Anaphylm (Dibutepinephrine) sublingual film [4][5]. - Investors are encouraged to join the class action and can contact the Investor Relations Manager for more information [2][3]. Group 2: Legal Representation - Individuals wishing to serve as lead plaintiff must file papers by May 4, 2026, but participation in any recovery does not require serving as lead plaintiff [3]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses [3]. Group 3: Law Firm Background - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [6].

Group 1 - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Aquestive securities during the Class Period have until May 4, 2026, to request appointment as Lead Plaintiff [2] - The lawsuit follows a significant stock price drop of 37.04%, closing at $3.91 per share after the announcement of FDA deficiencies regarding Anaphylm [5][4] Group 2 - The FDA's letter indicated ongoing review of the Anaphylm New Drug Application, delaying approval indefinitely [4] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history in fighting for victims of securities fraud [6]

Core Viewpoint - A securities class action lawsuit has been filed against Aquestive Therapeutics, Inc. on behalf of investors who purchased or acquired its securities between June 16, 2025, and January 8, 2026, alleging violations of the Securities Exchange Act of 1934 [1][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey, claiming that the company and certain senior officers made misrepresentations regarding the New Drug Application for Anaphylm (Dibutepinephrine) sublingual film [5][6]. - Investors are encouraged to join the class action and can contact the Investor Relations Manager for more information [3][9]. Group 2: Participation Information - Individuals wishing to serve as lead plaintiff must file papers by May 4, 2026, and participation does not require serving as lead plaintiff to share in any recovery [4]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its establishment in 1993 and has a strong track record in class action litigation [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's New Drug Application for Anaphylm [4][6]. Company Overview - Aquestive Therapeutics, Inc. is under scrutiny for allegedly providing false and misleading information regarding the approval timeline for its New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film [6]. - The company claimed confidence in the NDA submission and optimistic expectations for approval by the FDA's Prescription Drug User Fee Act (PDUFA) date of January 31, 2026 [6]. Legal Proceedings - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that the company concealed material adverse facts about the NDA, particularly regarding human factors in the use of its sublingual film [6]. Stock Performance - Following the announcement of deficiencies identified by the FDA in the NDA on January 9, 2026, Aquestive's stock price fell by more than 37% on the same day [7].

Core Viewpoint - A securities fraud class action lawsuit has been initiated against Aquestive Therapeutics, Inc. for alleged misrepresentations regarding its New Drug Application for Anaphylm (Dibutepinephrine) sublingual film, affecting investors who purchased securities between June 16, 2025, and January 8, 2026 [5][6]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey on behalf of investors who acquired Aquestive securities during the specified period [5]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [5]. Group 2: Investor Actions - Investors who purchased or acquired Aquestive securities are encouraged to discuss their legal rights and options, with a deadline to file as lead plaintiff by May 4, 2026 [3][4]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its inception in 1993 and has a strong track record in class action litigation [7].

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for allegedly providing misleading information regarding its New Drug Application for Anaphylm, leading to investor losses during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026 [1]. - Investors have until May 4, 2026, to seek appointment as lead plaintiff if they suffered losses during the Class Period [2]. - The complaint alleges that the defendants made positive statements while concealing material adverse facts about the NDA for Anaphylm [3]. Group 2: Regulatory Issues - On January 9, 2026, Aquestive announced it received a letter from the FDA identifying deficiencies that hindered labeling discussions for Anaphylm [3]. - The FDA's letter confirmed that the review of Anaphylm's NDA was ongoing, delaying approval beyond the January 31, 2026, Prescription Drug User Fee Act date [3]. Group 3: Company Background - Johnson Fistel, PLLP is a law firm specializing in shareholder rights and has recovered approximately $90.7 million for investors in previous cases [4].

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. (AQST) due to allegations of misleading statements regarding the company's New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film, which led to significant stock price declines for investors [1]. Summary by Relevant Sections Allegations - The complaint claims that Aquestive provided investors with positive statements while concealing material adverse facts about the NDA for Anaphylm, particularly regarding human factors in the use of the sublingual film [1]. - The company minimized the significance of packaging, use, administration, and labeling issues related to Anaphylm [1]. Stock Price Impact - Following the announcement of deficiencies identified by the FDA on January 9, 2026, the stock price of Aquestive fell from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026, marking a decline of over 37% in a single day [1]. Class Action Details - The class period for the lawsuit is defined as June 16, 2025, to January 8, 2026, with a deadline for shareholders to register for the class action set for May 4, 2026 [1]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [1].